Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 03, 2007. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of August 31, 2007, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a capital structure notification.
| Metric | Value |
|---|---|
| Issued Share Capital (as of Aug 31, 2007) | 6,022,370,916 Ordinary shares of 25p each |
| Treasury Shares | 377,027,158 Ordinary shares |
| Total Voting Rights | 5,645,343,758 |
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in capital structure or voting rights.
Guidance, Outlook, and Risks
The document contains no management commentary, future guidance, risk factors, contingencies, or discussion of unusual items. Its sole purpose is to provide the denominator for shareholder calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,645,343,758) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (377,027,158) to calculate the net outstanding share count.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for performance metrics.